GI254023X

Catalog No.S8660 Batch:S866002

Technical Data

Formula	C₂₁H₃₃N₃O₄
Molecular Weight	391.50	CAS No.	260264-93-5
Solubility (25°C)*	In vitro	DMSO	78 mg/mL (199.23 mM)
		Ethanol	37 mg/mL (94.5 mM)
		Water	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

GI254023X (GI 4023, SRI028594) is a selective inhibitor of ADAM10 with 100-fold selectivity for ADAM10 over ADAM17. The IC50 values for recombinant ADAM10 amd ADAM17 are 5.3 nM and 541 nM, respectively.GI254023X can inhibit MMP9.

Targets

ADAM10 ^[1]
(Cell-free assay)

5.3 nM

In vitro

In cell-based cleavage experiments GI254023X potently blocks the constitutive release of IL6R, CX3CL1 and CXCL16, which is in line with the reported involvement of ADAM10 but not ADAM17 in this process. By contrast, the compound does not affect the PMA-induced shedding^[2]. In addition to ADAM10 and ADAM17, GI254023X is a moderate inhibitor of ADAM9 with an IC50 of 280 nM^[1].

In vivo

Acute treatment with GI254023X in an AD mouse model substantially reduces brain LRP1 shedding and increases Aβ40 levels in the plasma, indicating enhanced Aβ transit from the brain to the periphery. Furthermore, both soluble and insoluble Aβ40 and Aβ42 brain levels are decreased following GI254023X treatment, but these effects lack statistical significance^[5].

Protocol (from reference)

Cell Assay:^{^[3]}	Cell lines HCA-7 cells Concentrations 3 μM Incubation Time 24 h Method HCA-7 cells are treated for 24 h with 0.1% DMSO, the metalloprotease inhibitors GI (GI254023X, ADAM10-selective, 3 µM) and GW (GW280264X, ADAM10- and ADAM17-selective, 3 µM), the pan-metalloprotease inhibitor Marimastat (MM; 10 µM), and the EGF-R kinase inhibitor AG1478 (10 µM). Cells stimulated with 100 ng/ml EGF served as positive control. Tyrosine-phosphorylated EGF-R and total EGF-R are assessed by Western blot analysis.
Animal Study:^{^[4]}	Animal Models BALB/c mice Dosages 200 mg/kg Administration i.p.

Cell Assay:^{^[3]}

Cell lines
HCA-7 cells
Concentrations
3 μM
Incubation Time
24 h
Method
HCA-7 cells are treated for 24 h with 0.1% DMSO, the metalloprotease inhibitors GI (GI254023X, ADAM10-selective, 3 µM) and GW (GW280264X, ADAM10- and ADAM17-selective, 3 µM), the pan-metalloprotease inhibitor Marimastat (MM; 10 µM), and the EGF-R kinase inhibitor AG1478 (10 µM). Cells stimulated with 100 ng/ml EGF served as positive control. Tyrosine-phosphorylated EGF-R and total EGF-R are assessed by Western blot analysis.

Animal Study:^{^[4]}

Animal Models
BALB/c mice
Dosages
200 mg/kg
Administration
i.p.

References

+ Expand

Selleck's GI254023X has been cited by 8 publications

MAP4K4 promotes ovarian cancer metastasis through diminishing ADAM10-dependent N-cadherin cleavage [ Oncogene, 2023, 42(18):1438-1452]	PubMed: 36922678
Elevated Kir2.1/nuclear N2ICD defines a highly malignant subtype of non-WNT/SHH medulloblastomas [ Signal Transduct Target Ther, 2022, 7(1):72]	PubMed: 35273141
IDO1 can impair NK cells function against non-small cell lung cancer by downregulation of NKG2D Ligand via ADAM10 [ Pharmacol Res, 2022, 177:106132]	PubMed: 35183714
Fewer LAG-3+ T Cells in Relapsing-Remitting Multiple Sclerosis and Type 1 Diabetes [ J Immunol, 2022, 208(3):594-602]	PubMed: 35022272
Pore-forming alpha-hemolysin efficiently improves the immunogenicity and protective efficacy of protein antigens [ PLoS Pathog, 2021, 17(7):e1009752]	PubMed: 34288976
Staphylococcus aureus α-Toxin Induces Acid Sphingomyelinase Release From a Human Endothelial Cell Line [ Front Microbiol, 2021, 12:694489]	PubMed: 34394034
Staphylococcus aureus α-toxin induces acid sphingomyelinase release from a human endothelial cell line [ bioRxiv, 2021, 10.1101/2021.03.29.437456]	PubMed: None
Partial Reduction of Amyloid β Production by β-Secretase Inhibitors Does Not Decrease Synaptic Transmission [ Alzheimers Res Ther, 2020, 26;12(1):63]	PubMed: 32456694

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.